Ensysce Biosciences (ENSC) Investor Presentation - Slideshow
Ensysce Biosciences(US:ENSC)2022-09-16 22:30NASDAQ: ENSC Improving Prescription Drug Safety Through Chemistry Investor Presentation September 2022 Disclaimer Ensysce's PF614 and nafamostat are currently in clinical and pre-clinical trials, involving both the TAAP platform and MPAR platform. Accordingly, PF614 and nafamostat have the risks and uncertainties inherent in any drug in trial-phase, which include, but are not limited to, a failure to show sufficient efficacy to obtain FDA approval, the risk that clinical trials may not confirm any safety, p ...